Is ranibizumab cost-effective for proliferative diabetic retinopathy?

This secondary analysis of the Protocol S trial compared the cost-effectiveness of ranibizumab versus laser for proliferative diabetic retinopathy.
Source: AAO

Posted in: Uncategorized

Leave a response

658 Malta Ave, Suite 101 Malta, NY 12020 (518) 580-0553